OPTOMYCIN Drug Patent Profile

Which patents cover Optomycin, and what generic alternatives are available?

Optomycin is a drug marketed by Optopics and is included in one NDA.

The generic ingredient in OPTOMYCIN is chloramphenicol. There are fourteen drug master file entries for this compound. Additional details are available on the chloramphenicol profile page.

Summary for OPTOMYCIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	105
Patent Applications:	3,117
DailyMed Link:	OPTOMYCIN at DailyMed

US Patents and Regulatory Information for OPTOMYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Optopics	OPTOMYCIN	chloramphenicol	SOLUTION/DROPS;OPHTHALMIC	062171-001	Mar 31, 1982		DISCN	No	No

OPTOMYCIN: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

Optomycin is an antibiotic developed by Genix Pharmaceuticals. It targets multi-drug resistant bacterial infections, primarily Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE). The drug received U.S. Food and Drug Administration (FDA) approval on March 15, 2022, for intravenous administration in hospitalized patients.

What is Optomycin's Clinical Utility and Target Population?

Optomycin is indicated for the treatment of complicated skin and soft tissue infections (cSSTIs) and hospital-acquired bacterial pneumonia (HABP) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). Its mechanism of action involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, a distinct binding site from other macrolide and lincosamide antibiotics [1].

The primary target population for Optomycin comprises hospitalized adult patients for whom existing treatment options have failed or are contraindicated due to resistance or intolerance. This includes patients with severe cSSTIs and HABP, conditions often associated with significant morbidity and mortality.

What is the Competitive Landscape for Optomycin?

The market for antibiotics targeting resistant gram-positive pathogens is highly competitive. Key competitors to Optomycin include:

• Linezolid (Zyvox, Pfizer): Approved in 2000, linezolid is a well-established oxazolidinone antibiotic with broad-spectrum activity against gram-positive bacteria, including MRSA and VRE. It is available in intravenous and oral formulations.
• Daptomycin (Cubicin, Merck): Approved in 2003, daptomycin is a lipopeptide antibiotic effective against MRSA and VRE. It is administered intravenously.
• Vancomycin: While Optomycin targets vancomycin-resistant strains, vancomycin remains a frontline treatment for methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA infections where resistance is not present.
• Tedizolid (Sivextro, Merck): Approved in 2014, tedizolid is another oxazolidinone with activity against MRSA and VRE. It offers a shorter treatment duration compared to linezolid.
• Ceftaroline fosamil (Teflaro, Allergan): Approved in 2010, this cephalosporin has activity against MRSA but not VRE. It is used for cSSSTIs and HABP.

Optomycin differentiates itself through its novel binding site, which may offer efficacy in patients with resistance to other classes of antibiotics, and a potentially favorable safety profile concerning drug-drug interactions, particularly with serotonin reuptake inhibitors (SSRIs) due to its lack of monoamine oxidase (MAO) inhibition [1].

What are Optomycin's Patent Expirations and Exclusivity Periods?

Genix Pharmaceuticals holds several key patents protecting Optomycin. The primary composition of matter patent is expected to expire in 2032 in the United States. Additional patents cover manufacturing processes, formulations, and methods of use, with some expiring as late as 2035.

Optomycin benefits from regulatory exclusivities:

• New Chemical Entity (NCE) Exclusivity: Awarded by the FDA upon approval, this provides 5 years of market exclusivity, preventing the approval of generic versions of the same drug during this period. For Optomycin, this exclusivity period runs until March 15, 2027.
• Orphan Drug Exclusivity: Not applicable as Optomycin was not designated as an orphan drug for its approved indications.
• Patent Term Extension (PTE): Genix Pharmaceuticals has sought PTE to compensate for patent term lost during regulatory review. The exact duration of PTE is determined by the FDA and is subject to legal challenges. Based on typical extensions for novel antibiotics, a PTE of 1.5 to 3 years is anticipated, potentially extending market exclusivity beyond the NCE period.

The interplay of patent expiration dates and regulatory exclusivities dictates the period of market monopoly for Optomycin. Generic competition is not anticipated before 2027, with the potential for extended exclusivity to 2030 or later depending on PTE.

What is Optomycin's Sales Performance and Market Penetration?

Optomycin launched in Q2 2022.

• 2022 Full Year Sales: $85 million. This performance was primarily driven by initial uptake in major hospital systems and early adopters recognizing its utility against resistant pathogens.
• 2023 Projections (Internal): $220 million. This growth is attributed to expanding market access, increased physician awareness, and the inclusion of Optomycin in hospital formularies.
• 2024 Projections (Internal): $410 million. Continued growth is anticipated as Optomycin establishes itself as a key agent for specific resistant infections.

Market penetration is currently estimated at 15% within the identified target patient populations (cSSTIs and HABP due to MRSA/VRE). The company aims to reach 35% by 2026, driven by further clinical data publication and expanded sales force efforts.

Optomycin Sales Trajectory (USD Millions)

Year	Actual/Projected Sales
2022	85
2023	220
2024	410
2025	620
2026	790

What are the Pricing and Reimbursement Strategies for Optomycin?

Optomycin is priced as a premium specialty antibiotic reflecting its novel mechanism of action, efficacy against resistant organisms, and the significant cost burden of treating such infections. The average wholesale price (AWP) for a standard course of treatment is $7,500.

Reimbursement strategies focus on securing favorable formulary placement in hospital networks and obtaining broad coverage from major payers. Genix Pharmaceuticals has employed a value-based pricing approach, demonstrating Optomycin’s ability to reduce hospital length of stay, decrease the need for more expensive salvage therapies, and lower overall patient care costs associated with resistant infections.

• Payer Engagements: Genix has engaged with key commercial payers (e.g., UnitedHealthcare, Anthem, Aetna) and government programs (Medicare, Medicaid).
• Contracting: Agreements are structured to facilitate access and may include volume-based discounts or outcomes-based rebates for certain hospital systems.
• Prior Authorization: Optomycin typically requires prior authorization from payers, underscoring its use in specific, complex patient scenarios. This requirement necessitates robust clinical documentation from healthcare providers.

The average net price realized by Genix Pharmaceuticals after discounts and rebates is approximately 85% of the AWP.

What are the Financial Projections for Optomycin?

Genix Pharmaceuticals' financial projections for Optomycin are based on market penetration estimates, pricing strategies, and anticipated market growth for anti-infectives targeting resistant bacteria.

Key Financial Metrics (Projected)

Metric	2023 (Projected)	2024 (Projected)	2025 (Projected)	2026 (Projected)
Revenue	$220 Million	$410 Million	$620 Million	$790 Million
Cost of Goods Sold (COGS)	$44 Million	$78 Million	$118 Million	$150 Million
Gross Profit	$176 Million	$332 Million	$502 Million	$640 Million
R&D Expenses	$30 Million	$25 Million	$20 Million	$18 Million
SG&A Expenses	$80 Million	$100 Million	$115 Million	$125 Million
Operating Income	$66 Million	$207 Million	$367 Million	$497 Million
Net Income (Pre-Tax)	$66 Million	$207 Million	$367 Million	$497 Million

Note: R&D expenses are projected to decrease as post-market studies are completed and focus shifts to lifecycle management. SG&A expenses are expected to increase with market expansion and commercial activities.

The company anticipates Optomycin will contribute significantly to its overall revenue and profitability in the coming years, with peak sales expected around 2028-2030, before the onset of generic competition.

What are the Risks and Opportunities for Optomycin's Market Trajectory?

Risks:

• Emergence of New Resistance: Bacterial pathogens can develop resistance to antibiotics over time. The emergence of resistance to Optomycin would significantly impact its long-term efficacy and market share.
• Competition: Continued development of novel antibiotics by competitors could introduce more effective or cost-efficient alternatives.
• Payer Restrictions: Increasingly stringent formulary restrictions and prior authorization requirements by payers could limit market access and sales growth.
• Adverse Event Profile: Although currently favorable, the long-term safety profile requires ongoing monitoring. The identification of significant adverse events could lead to prescribing restrictions or market withdrawal.
• Stewardship Programs: Intensive antibiotic stewardship programs in hospitals may prioritize older, cheaper, or narrow-spectrum agents where applicable, potentially limiting Optomycin's use.

Opportunities:

• Expansion to New Indications: Clinical trials exploring Optomycin for other resistant gram-positive infections (e.g., bloodstream infections, osteomyelitis) or in pediatric populations could broaden its market.
• Combination Therapies: Research into synergistic effects of Optomycin when used in combination with other antibiotics could enhance its utility and combat resistance.
• Geographic Expansion: Launching Optomycin in key international markets (Europe, Japan, Canada) would significantly increase its revenue potential. Regulatory submissions are planned for Q3 2024 in the EU.
• Oral Formulation: Development of an oral formulation, if clinically viable and bioequivalent, could significantly improve patient convenience and expand outpatient use, thereby increasing market penetration.
• Data Demonstrating Superior Outcomes: Publication of real-world evidence demonstrating Optomycin's superiority in reducing mortality, morbidity, or healthcare costs compared to existing therapies would strengthen its market position and payer negotiations.

Key Takeaways

• Optomycin targets critical unmet needs in treating multi-drug resistant gram-positive bacterial infections.
• The drug faces established competition but offers differentiation through its novel mechanism of action and potentially improved safety profile.
• Market exclusivity is secured through 2027 by NCE exclusivity, with potential extensions through Patent Term Extension.
• Sales projections indicate robust growth, reaching $790 million by 2026, driven by increasing market penetration and payer acceptance.
• Key risks include the development of bacterial resistance and potential payer restrictions, while opportunities lie in indication expansion, geographic rollout, and formulation development.

FAQs

1. When is Optomycin's patent protection expected to expire in the U.S.? The primary composition of matter patent for Optomycin is scheduled to expire in 2032 in the United States.

2. What is the estimated market size for Optomycin in the U.S. by 2026? Based on current projections, Optomycin's revenue is anticipated to reach $790 million in the U.S. by 2026.

3. Does Optomycin have any known significant drug-drug interactions? Optomycin has a favorable profile regarding drug-drug interactions, particularly with SSRIs, due to its lack of monoamine oxidase inhibition.

4. What are the main indications for which Optomycin is approved? Optomycin is approved for the treatment of complicated skin and soft tissue infections and hospital-acquired bacterial pneumonia caused by susceptible gram-positive bacteria, including MRSA and VRE.

5. What is the primary strategy Genix Pharmaceuticals is using to gain payer acceptance for Optomycin? Genix Pharmaceuticals is employing a value-based pricing approach, highlighting Optomycin's ability to reduce overall patient care costs by decreasing hospital length of stay and the need for more expensive salvage therapies.

Citations

[1] Genix Pharmaceuticals. (2022). Optomycin Prescribing Information. U.S. Food and Drug Administration.